Results showed that subjects taking the probiotic formulation experienced a significantly larger reduction in LDL cholesterol and total cholesterol after 12 weeks, compared to placebo.
Kaneka Probiotics has announced the publication of a study1 demonstrating the effects of its Cardio Probiotic on serum cholesterol levels. In the study, 91 subjects with a median age of 63.5 and untreated LDL cholesterol greater than 160 mg/dL were randomized to receive either placebo of the Cardio Probiotic, once daily for 12 weeks. The Cardio Probiotic consists of three strains of Lactobacillus plantarum (L. plantarum KABP -011, -012, and -013).
Results showed that subjects taking the probiotic formulation experienced a significantly larger reduction in LDL cholesterol and total cholesterol after 12 weeks, compared to placebo. These effects were also more pronounced in subjects with higher LDL cholesterol levels at baseline.
“Our Cardio strains are very potent producers of Bile Salt Hydrolase enzyme, which is one of the key mechanisms mediating cholesterol decline,” explained Mike Kolifrath, vice president, sales and marketing of the Probiotics Division at Kaneka, in a press release. “This is not a trait shared by all probiotics, so we are confident that innovative brands will incorporate Cardio into their cardiovascular formulations.”
Reference
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.